Board of Directors
Pini Orbach, PhD Chairman
Dr. Orbach is the Head of the Pharma Division of Arkin Holdings and a member of the board at several of its pharmaceutical companies, including UroGen Pharma and Quiet Therapeutics, from which he shares his extensive hands-on drug development and business experience. He originally gained his foundation in US based companies such as, Arisaph Pharmaceuticals and Epix Pharmaceuticals (NASDAQ, EPIX), as well as Israeli-based companies such as, cCAM BioTherapeutics - a cancer immunotherapy company, which was sold to Merck in 2015 for $605M. He holds a PhD from the University of Florida, and was a postdoctoral fellow at Harvard Medical School - Massachusetts General Hospital.
Briggs Morrison, MD
Dr. Morrison, currently serving as an Executive Partner at MPM Capital and CEO at Syndax, served as Chief Medical Officer and Executive Vice President for Global Medicines Development at AstraZeneca and Head of Global Medicines Development at AstraZeneca, where he oversaw all clinical development functions and late-stage clinical development projects. Prior to that, Dr. Morrison served as Head of Clinical Development at Pfizer, where he oversaw Phase 1-3 development and operations for all therapeutic areas before being appointed the Head of Development, Medical Affairs, Safety and Regulatory Affairs for all Pfizer human health businesses. Dr. Morrison earned his M.D. from the University of Connecticut and completed his training in Internal Medicine at Massachusetts General Hospital and in Medical Oncology at the Dana-Farber Cancer Institute. He also completed a post-doctoral research fellowship in the Department of Genetics at Harvard Medical School and additional post-doctoral work at the Dana-Farber Cancer Institute. He received his B.S. in Biology from Georgetown University.
Gary Gordon, MD, PhD
Dr. Gordon is an accomplished pharmaceutical executive with an extensive experience in Oncology across all phases of clinical development. Dr. Gordon, currently serving as Venture Advisor at Israel Biotech Fund, served as Vice President, Oncology Development at AbbVie, where he oversaw the development of AbbVie’s oncology projects and helped expand the oncology pipeline. He played a critical role in the oncology business expansion which included the approval of venetoclax, several major acquisitions, multiple Break Through and Orphan Drug Designations, and a development portfolio of nearly 200 studies in approximately 50 countries. Prior to AbbVie, Dr. Gordon served as senior oncology roles including Divisional Vice President, Global Oncology Development at Abbot and as Chief Scientific Officer at Ovation Pharmaceuticals, and other roles at Pharmacia and G.D. Searle Company. Prior to his career in the pharmaceutical industry, Dr. Gordon was an Associate Professor of Medical Oncology at the Johns Hopkins University School of Medicine. He holds an M.D. and Ph.D. from the Johns Hopkins University School of Medicine where he also completed his residency, fellowship and postdoctoral training.
Mr. Sasson is a member of the Board of Directors of CancerLinQ™ LLC, a subsidiary of the American Society of Clinical Oncology (ASCO) established for the development and operations of the CancerLinQ™ initiative, as well as The Conquer Cancer Foundation (CCF) of the American Society of Clinical Oncology (ASCO), which seeks dramatic advances in the prevention, diagnosis, treatment, and cure of all types of cancer.
Mr. Sasson is also the founder of several technology comapnies, lead by Mr. Sasson to technological and commercial success.
Liora Ettinger, MBA
Mrs. Ettinger is the CEO of Michael Ilan Management and Investment Ltd. Mrs. Ettinger obtained a B.A. in Economics and Business Administration (Highest Honors) from Bar-Ilan University, and an MBA with a specialization in Finance and Accounting from Tel Aviv University. She has been involved in financial management in leading Israeli companies and foreign markets, specializing in corporate finance, deal structuring, public offerings, M&A, and business analysis.
Ruth Ben Yakar, PhD CEO
Dr. Ben Yakar brings Biosight over 20 years of experience at various executive positions in the biotech industry, leading diverse corporate, financial, business, operational, clinical, and regulatory activities. Prior to joining Biosight, Dr. Ben Yakar served in several executive management positions in the pharmaceutical industry, including CEO of Procognia, a public biotech company, and CEO of Thrombotech, a Phase 2b biotech company she led towards acquisition. Prior to that, Dr. Ben Yakar served as the Chief Business Officer of YEDA, the technology transfer company of the Weizmann Institute of Science, where she oversaw the business aspects of all licensing deals of the Weizmann Institute of Science, and as Vice President at Gamida Cell. Dr. Ben Yakar also served as a Director at biotech companies traded on Nasdaq, Zurich, and TASE, and at Israel Advanced Technology Industries organization, and is a member of 8400 Cohort 1. Dr. Ben Yakar holds a PhD Cum Laude in molecular cell biology from the Weizmann Institute of Science.